EORTC presents at San Antonio Breast Cancer Symposium
4 Dec 2017
The EORTC will present five abstracts at San Antonio Breast Cancer Symposium (SABCS) from 5 to 9 December 2017. Find when and where below:
Poster Presentation
- Quality of life (QoL) in male breast cancer (BC): Prospective study of the EORTC10085/TBCRC029/BIG2-07/NABCG International male BC program
Time: Friday, December 8, 5:00 pm – 7:00 pm
Location: P5-23-02
Authors: Schroder C, Cardoso F, Dijkstra N, van Leeuwen-Stok E, Linderholm B, Morgenstern D, Van Poznak C, Wolff A, Poncet C, Gomez HL, Aalders K, Bjelic-Radisic V, Werutsky G, Tryfonidis K, Coens C, Giordano SH, Ruddy KJ.
- Clinical and biological characterization of male breast cancer (BC) EORTC 10085/TBCRC 029/BOOG 2013-02/BIG 2-07: Baseline results from the prospective registry
Time: Friday, December 8, 5:00 pm – 7:00 pm
Location: P5-23-01
Authors: Giordano SH, Schröder CP, Poncet C, van Leeuwen-Stok E, Linderholm B, Abreu MH, Rubio I, Van Poznak C, Morganstern D, Cameron D, Vleugel MM, Smilde TJ, Bozovic-Spasojevic I, Korde L, Russell NS, den Hoed IDM, Honkoop AH, van der Velden AWG, van ‘t Riet M, Dijkstra N, Bogler O, Goulioti T, Hilsenbeck S, Ruddy KJ, Wolff A, van Deurzen CHM, Martens J, Bartlett JMS, Aalders K, Tryfonidis K, Cardoso F.
- Molecular subtyping of male breast cancer by the International male breast cancer program (IMBC): EORTC 10085/TBCRC 0-29/BIG 2-07/NABCG/BOOG 2009-04
Time: Friday, December 8, 7:00 am – 9:00 am
Location: PD7-12
Authors: Martens JWM, Sieuwerts A, Ponchet C, Smid M, de Weerd V, Slaets L, Piper T, van Deurzen CHM, Schroder CP, Stangle C, Kloosterman W, van Leeuwen-Stok E, Nilsson C, Vermeij J, Peeters S, Goulioti T, Nowaczyk M, Aebi S, Rubio IT, Kelly C, Bayani J, Porter P, Murray M, Hudis C, Middleton L, Korde L, Ruddy K, Winer E, Bogler O, van den Weyngaert D, dal Lago L, Fraser J, Benstead K, van Asperen C, Linderholm B, Hedenfalk I, Tryfonidis K, Giordano S, Bartlett J, Cardoso F.
- Young age and the risk of disease recurrence as assessed by the 70-gene signature: an analysis from the EORTC 10041/BIG 03-04 MINDACT trial
Time: Wednesday, December 6, 5:00 pm – 7:00 pm
Location: P1-07-08
Authors: Aalders K, Genbrugge E, Poncet C, Kuijer A, Pistilli B, Piccart M, Tryfonidis K, van Dalen T, Cardoso F, van ‘t Veer L, Rutgers E.
- Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2- positive metastatic breast cancer: Results from the EORTC 75111- 10114 ETF/BCG randomized phase II study
Time: Thursday, December 7, 7:00 am – 9:00 am
Location: PD3-09
Authors: Wildiers H, Tryfonidis K, dal Lago L, Vuylsteke P, Curigliano G, Waters S, Brouwers B, Aalders K, Meulemans B, Litiere S, Touati N, Cardoso F, Brain E.
Related News
EORTC calls for a balanced and feasible European Health Data Space (EHDS)
8 Jul 2026
Professor Benjamin Besse becomes President of EORTC
26 Jun 2026
CCTG, EORTC and UK3CR welcome G7 commitment to accelerate global progress against cancer
24 Jun 2026
EORTC welcomes EU Biotech Act and calls for refinements to enable patient-centred trials
24 Jun 2026
New study confirms a key quality of life tool can be used with adolescents with cancer
9 Jun 2026
“Changing practice, improving lives”: EORTC publishes its Annual Report 2025
8 Jun 2026
This Clinical Trials Day, EORTC announces the upcoming Summit for Clinical Cancer Research
20 May 2026
Long-term EORTC trial challenges assumptions about lymph node radiation therapy in breast cancer
17 May 2026
Multinational study provides new evidence for the value of response-adapted, personalised treatment in Hodgkin lymphoma
1 May 2026
EORTC’s presence at ESTRO 2026
30 Apr 2026
